Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer

Clinical Endocrinology

Volumn 52, Issue 6, 2000, Pages 681-685

  De Marinis, L ^a,c   Mancini, A ^a   Izzi, D ^a   Blanchi, A ^a   Giampietro, A ^a   Fusco, A ^a   Liberale, I ^a   Rossi, S ^a   Valle, D ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b Eli Lilly Italia   (Italy)

^c Via Cassia 901 ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LUTEINIZING HORMONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DRUG EFFECT; DRUG MECHANISM; FEMALE; GROWTH HORMONE RELEASE; HORMONE DETERMINATION; HORMONE RESPONSE; HUMAN; IMMUNORADIOMETRIC ASSAY; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; AREA UNDER CURVE; BREAST NEOPLASMS; DEPRESSION, CHEMICAL; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LUTEINIZING HORMONE; MIDDLE AGED; PROLACTIN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEX HORMONE-BINDING GLOBULIN; TAMOXIFEN;

EID: 0034053631     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2000.00991.x     Document Type: Article

References (34)

1. Bates, S., Davidson, N., Valverius, E., Freter, C.E., Dixon, R.B., Tam, J.P., Kudlaw, J.E., Lippman, M.E. & Salomon, D.S. (1988) Expression of transforming growth factor alpha and its mRNA in humane breast cancer: its regulation by estrogen and its possible functional significance. Molecular Endocrinology, 2, 543-555.
2. Berelowitz, M., Szsabo, M., Frohman, L.A., Firestones, S., Chu, L. & Hintz, R.L. (1981) Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science, 212, 1279.
3. Blum, W.F., Algertsson-Wikland, K., Rosberg, S. & Ranke, M.B. (1993) Serum levels of insulin-like growth-factor (IGF-1) and IGF binding protein 3 (IGF-BP3) reflect spontaneous growth hormone secretion. Journal of Clinical Endocrinology and Metabolism, 76, 1610-1616.
4. Casanueva, F.F., Borras, C.G., Burguera, B., Lima, L., Muruais, C., Tresguerres, J.A.F. & Devesa, J. (1987) Growth hormone and prolactin secretion after growth hormone-releasing hormone administration, in anorexia nervosa patients, normal controls and tamoxifen-pretreated volunteers. Clinical Endocrinology, 27, 517-523.
5. Cocconi, G., Bella, M., Calabresi, F., Tonato, M., Canaietti, R., Boni, C., Buzzi, F., Ceci, G., Corona, E., Costa, P., Lottici, R., Papadia, F., Sofra, M.C. & Bacchi, M. (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New England Journal of Medicine, 327, 516-523.
6. Colletti, R.B., Roberts, J.D., Devlin, J.T. & Copeland, K.C. (1989) Effect of tamoxifen on plasma insulin-like growth factor I levels of stage I breast cancer patients. Cancer Research, 49, 1882-1884.
7. Corsello, S.M., Rota, C.A., Putignano, P., Della Casa, S., Barbabei, A., Migneco, M.G., Vangeli, V., Barini, A., Mandalà, M., Barone, C. & Barbarino, A. (1998) Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer. European Journal of Endocrinology, 139, 309-313.
8. Cozzi, R., Attanasio, R., Oppizzi, G., Orlandi, P., Giustina, A., Lodrini, S., Da Re, N. & Dallabonzana, D. (1997) Effects of tamoxifen on GH and 1GF-I levels in acromegaly. Journal of Endocrinological Investigation, 20, 445-451.
9. De Marinis, L., Mancini, A., Giampietro, A., Valle, D., Agresti, M., De Crea, C., Rossi, S. & Bellantone, R. (1996) Effect of a tamoxifen chronic treatment on the GHRH-induced GH release: preliminary data. Journal of Endocrinology, 148 (Suppl.), P165.
10. Friedl, A., Jordan, V.C. & Pollack, M. (1992) Effect of tamoxifen on insulin-like growth factor I levels in breast cancer patients (abstract). Proceedings of American Society of Clinical Oncology, 11, 52.
11. Fornander, T., Rutqvist, L.E., Wilking, N., Carlstrom, K. & von Schoultze, B. (1993) Oestrogenic effects of adjuvant tamoxifen in post-menopausal breast cancer. European Journal of Cancer, 29A, 497-500.
12. Frohlander, N. & von Schoultz, B. (1988) Growth hormone and somatomedin C during post-menopausal replacement therapy with oestrogen alone and in combination with an antioestrogen. Maturitas, 9, 297-302.
13. Giustina, A. & Veldhuis, J.D. (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews, 19, 717-797.
14. Huynh, H.T., Tetenes, E., Wallace, L. & Pollak, M. (1993) In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Research, 53, 1727-1730.
15. Juul, A., Main, K., Blum, W.F., Lindholm, J., Ranke, M.B. & Skakkebaek, N. (1994) The ratio between serum levels of insulin-like growth-factor (IGF-1 ) and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clinical Endocrinology, 41, 85-93.
16. Knabbe, C., Lippman, M., Wakefield, L., Flanders, K.C., Kasid, A., Derynck, R. & Dixon, R.B. (1987) Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48, 417-428.
17. Lerner, L. & Jordan, V. (1990) Development of antiestrogens and their use in breast cancer. Cancer Research, 50, 4177-4189.
18. Lonning, P.E., Hall, K., Aakvaag, A. & Lien, E.A. (1992) Influence of tamoxifen on plasma levels of insulin-like growth factor 1 and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research, 52, 4719-4723.
19. Lonning, P.E., Johannessen, D.C., Lien, E.A., Ekse, D., Fotsis, T. & Aldercreutz, H. (1995) Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in post-menopausalbreast cancer patients. Journal of Steroid Biochemistry Molecular Biology, 52, 491-496.
20. Malaab, S.A., Pollak, M.N. & Goodyer, C.G. (1992) Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. European Journal of Cancer, 28A, 788-793.
21. Mancini, A., Fiumara, C., Conte, G., Valle, D., Iacona, T., Chiari, D., Lombardi, C.P., Rossi, S., Menini, E. & De Marinis, L. (1992) Plasma SHBG and IGF-1 concentration in pre- and post-menopausal women with benign breast disease. In: Recent Developments in Gynecological Endocrinology, (eds A.R. Genazzani, A.D. Genazzani & G.D'Ambrogio), pp. 517-522. Parthenon Publishing, Carnforth, UK.
22. Metzger, D.L. & Kerrigan, J.R. (1994) Estrogen receptor blockade with famoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence. Journal of Clinical Endocrinology and Metabolism, 79, 513-518.
23. Murphy, L.J. & Friesen, H.G. (1998) Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor 1 gene expression in the ovariectomized hypophysectomized rat. Endocrinology, 122, 325-332.
24. Paavonen, T., Aronen, H. & Pyrhonen, S. (1991) The effects of antiestrogen therapy on lymphocytes functions in breast cancer patients. APMIS, 99, 163.
25. Paterson, A.G., Turkes, A., Groom, G.V. & Webster, D.J. (1983) The effect of tamoxifen on plasma growth hormone and prolactin in postmenopausal women with advanced breast cancer. European Journal of Cancer Clinical Oncology, 19, 919-922.
26. Pollak, M., Costantino, J., Polychronakos, C., Blauer, S., Guyda, H., Redmond, C., Fisher, B. & Margolese, R. (1990) Effect of tamoxifen on serum insulin-like growth factor 1 levels in stage I breast cancer patients. Journal of National Cancer Institute, 82, 1693-1697.
27. Pollak, M., Huynh, H. & Lefebvre, S. (1991) Tamoxifen reduces serum insulin-like growth factor 1. Breast Cancer Research. Treatment, 22, 91-100.
28. Pollak, M., Sem, A.W., Richard, M., Tetenes, E. & Bell, R. (1992) Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. Journal of National Cancer Institute, 84, 966-971.
29. von Schoultz, B. & Carlstrom, K. (1989) General review on the regulation of sex hormone binding globulin. Journal of Steroid Biochemistry, 32, 327-334.
30. Stewart, A., Johnson, M., May, F. & Westley, B. (1990) Role of insulin-like growth factors and the type 1 IGF receptor in the estrogen-stimulated proliferation of human breast cancer cells. Journal of Biological Chemistry, 265, 21172-22178.
31. Stracke, M.L., Kohn, E.C., Aznavoorian, S.A., Wilson, L.L., Salomon, D., Krutzsch, H.C., Liotta, L.A. & Schiffmann, E. (1988) Insulin-like growth factors stimulate chemotaxis in human melanoma cells. Biochemical Biophysical Research Communication, 153, 1076-1083.
32. Tannenbaum, G.S., Gurd, W., Lapointe, M. & Pollak, M. (1992) Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology, 130, 3395-3401.
33. Weissberger, A.J. & Ho, K.K.Y. (1993) Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization. Journal of Clinical Endocrinology and Metabolism, 76, 1407-1412.
34. Yee, D., Paik, S., Lebovic, G.S., Marcus, R.R., Favoni, R.E., Cullen, K.J., Lippman, M.E. & Rosen, N. (1989) Analysis of insulin-like growth factor 1 gene expression in malignancy: evidence for a paracrine role in human breast cancer. Molecular Endocrinology, 3, 517-519.